Novel Assays for Detection of Influenza Virus

The University of Hong Kong (HKU)

Status: Withdrawn

Conditions: Influenza A Virus

Treatments: Diagnostic Test: PB2 gene RT-PCR; NS gene RT-PCR

Study type: Observational

Funder types: Other

Identifiers

NCT03924284

FluA_20190110

Details and patient eligibility

About

Seasonal influenza virus causes an estimated 0.3-0.6 million deaths per year. Avian influenza virus H5N1, H7N9 and H5N6 has fatality rate of over 30%. Swine influenza viruses from pigs have also infected humans.

Molecular assays are now used routinely in the detection of influenza viruses. The M gene is often used as the target for all influenza A viruses because the nucleotide sequence of this gene is relatively conserved among all the influenza A viruses. The World Health Organization and the US Centers for Disease Control and Prevention (CDC) have published protocols for molecular detection of influenza A virus M gene.

However, recent studies have shown that mutations in the M gene have led to a reduced sensitivity of RT-PCR assay targeting this gene. Therefore, it is important to use alternative conserved genes as the target of RT-PCR. In this study, our aim is to evaluate two new RT-PCR assays that are based on PB2 and NS gene segment.

Full description

I. Background

• Seasonal influenza virus causes an estimated 0.3-0.6 million deaths per year. Avian influenza virus H5N1, H7N9 and H5N6 has fatality rate of over 30%. Swine influenza viruses from pigs have also infected humans.
• Molecular assays are now used routinely in the detection of influenza viruses. The M gene is often used as the target for all influenza A viruses because the nucleotide sequence of this gene is relatively conserved among all the influenza A viruses. The World Health Organization and the US Centers for Disease Control and Prevention (CDC) have published protocols for molecular detection of influenza A virus M gene.
• However, recent studies have shown that mutations in the M gene have led to a reduced sensitivity of RT-PCR assay targeting this gene. Therefore, it is important to use alternative conserved genes as the target of RT-PCR. In this study, our aim is to evaluate two new RT-PCR assays that are based on PB2 and NS gene segment

II. Study objective -To evaluate the sensitivity and specificity of 2 new RT-PCR assays

III. Overall study design

• The investigators will randomly retrieve archived nasopharyngeal and saliva specimens that were previously tested for influenza A virus using commercially available assays in our laboratory, tested for influenza A virus at the Public Health Laboratory Service Branch in Hong Kong. These specimens will be tested for influenza A virus by 4 different RT-PCR assays as listed below:

  1. Our new RT-PCR assay targeting PB2 gene

  2. Our new RT-PCR assay targeting NS gene

  3. M gene RT-PCR published by the World Health Organization

  4. M gene RT-PCR published by the US CDC

     Sensitivity, specificity, positive predictive value and negative predictive value will be determined.

     IV. Nucleic acid extraction and real-time reverse transcription-polymerase chain reaction (RT-PCR) for influenza A virus

• Saliva and nasopharyngeal specimens will be subjected to total nucleic acid (TNA) extraction by NucliSENS easyMAG (BioMerieux, Boxtel, Netherlands).

• Monoplex real-time RT-PCR assays for influenza A virus will be performed. The primers and probes for the M gene RT-PCR have been published by the WHO and the US CDC.

V. Sample size:

• The investigators will perform all 4 RT-PCR assays on a total of 320 specimens, including
• 80 nasopharyngeal specimens which tested positive for influenza A by commercially-available molecular assays or by testing performed at the Public Health Laboratory Services Branch in Hong Kong
• 80 nasopharyngeal specimens which tested negative for influenza A by commercially-available molecular assays or by testing performed at the Public Health Laboratory Services Branch in Hong Kong
• 80 saliva specimens which tested positive for influenza A by commercially-available molecular assays
• 80 saliva specimens which tested negative for influenza A by commercially-available molecular assays

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Nasopharyngeal or saliva specimens of patients in Queen Mary Hospital of Hong Kong
• Tested for influenza A virus using a commercially available assay or by the Public Health Laboratory Services Branch in Hong Kong

Exclusion criteria

• Insufficient specimen volume

Trial design

0 participants in 4 patient groups

NPA positive

Description:

NPA specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong

Treatment:

Diagnostic Test: PB2 gene RT-PCR; NS gene RT-PCR

NPA negative

Description:

NPA specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong

Treatment:

Diagnostic Test: PB2 gene RT-PCR; NS gene RT-PCR

Saliva positive

Description:

Saliva specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong

Treatment:

Diagnostic Test: PB2 gene RT-PCR; NS gene RT-PCR

Saliva negative

Description:

Saliva specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong

Treatment:

Diagnostic Test: PB2 gene RT-PCR; NS gene RT-PCR